RARS2 Inhibitors
Chemical inhibitors of arginyl-tRNA synthetase (RARS2) operate by impeding various stages of protein synthesis, which is essential for the proper functioning of this enzyme. Puromycin is known to cause premature chain termination during the translation process. By doing so, it inhibits the elongation of peptide chains, which directly impacts the role of RARS2 in attaching arginine to its corresponding tRNA. Similarly, Anisomycin disrupts protein synthesis by inhibiting peptidyl transferase activity, which is crucial for peptide bond formation. This inhibition leads to a reduced availability of polypeptide chains that require arginylation, an activity central to RARS2's function. Cycloheximide and Emetine both target the translocation step in different ways, with cycloheximide affecting the eukaryotic ribosome and emetine acting on ribosomal movement along mRNA. These actions result in a diminished pool of polypeptides and tRNAs with which RARS2 can interact, thereby indirectly reducing its activity.
Further impacting RARS2 are chemicals that affect the initiation and elongation phases of protein synthesis. Harringtonine and Omacetaxine mepesuccinate block the peptidyl transferase reaction and initial elongation step of translation, respectively. This leads to a decreased demand for RARS2's aminoacylation activity, as fewer nascent peptides are being elongated. Pactamycin's binding to the 30S ribosomal subunit results in the inhibition of the initiation of protein synthesis, which indirectly affects RARS2 by reducing mitochondrial translation processes. Fusidic acid uniquely freezes the ribosome during protein synthesis by preventing the turnover of elongation factor G (EF-G), which stalls the translation process where RARS2 is active. Lastly, Sparsomycin binds to the peptidyl transferase center, directly inhibiting the enzyme's activity and thus hindering the synthesis of proteins that RARS2 would typically arginylate. Each of these inhibitors, by targeting different steps within the protein synthesis pathway, contributes to the indirect inhibition of the essential functions performed by RARS2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin inhibits protein synthesis by causing premature chain termination during translation. This action of puromycin can lead to the functional inhibition of RARS2 as it halts the elongation of peptide chains, thus preventing RARS2 from carrying out its role in aminoacylating tRNA with arginine. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $53.00 | 10 | |
Chloramphenicol binds to the bacterial ribosome and inhibits protein synthesis. Although RARS2 is a mitochondrial protein, chloramphenicol can inhibit mitochondrial protein synthesis, which can indirectly inhibit the function of RARS2 by preventing its incorporation into functional complexes within the mitochondria. | ||||||
Tetracycline | 60-54-8 | sc-205858 sc-205858A sc-205858B sc-205858C sc-205858D | 10 g 25 g 100 g 500 g 1 kg | $62.00 $92.00 $265.00 $409.00 $622.00 | 6 | |
Tetracycline binds to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis. Similar to chloramphenicol, tetracycline can affect mitochondrial protein synthesis and thereby indirectly inhibit RARS2 function. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in the ribosome. Inhibiting overall protein synthesis can indirectly reduce the activity of RARS2 by limiting its interaction with newly synthesized polypeptide chains and its substrate tRNAs. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin interferes with protein synthesis by inhibiting peptidyl transferase activity of the ribosome. By hindering peptide bond formation, it indirectly inhibits RARS2 by limiting the availability of elongated polypeptides that require arginylation. | ||||||
Harringtonin | 26833-85-2 | sc-204771 sc-204771A sc-204771B sc-204771C sc-204771D | 5 mg 10 mg 25 mg 50 mg 100 mg | $195.00 $350.00 $475.00 $600.00 $899.00 | 30 | |
Harringtonine inhibits protein synthesis by blocking the peptidyl transferase reaction. This action indirectly inhibits RARS2 by preventing the elongation of nascent peptides, reducing the demand for its aminoacylation activity. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $352.00 $566.00 $1331.00 $2453.00 | ||
Emetine blocks protein synthesis by inhibiting the movement of ribosomes along mRNA. This blockade can indirectly inhibit RARS2 by diminishing the use of arginyl-tRNA in protein synthesis within the mitochondria. | ||||||
Fusidic acid | 6990-06-3 | sc-215065 | 1 g | $292.00 | ||
Fusidic acid prevents turnover of elongation factor G (EF-G) from the ribosome, effectively freezing the ribosome during protein synthesis. This indirectly inhibits RARS2 by stalling the translation process in mitochondria where RARS2 operates. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $51.00 $123.00 $178.00 | 11 | |
Omacetaxine inhibits protein synthesis by preventing the initial elongation step of translation. This inhibition can indirectly affect RARS2 by reducing the overall rate of protein synthesis, thereby diminishing the functional demand for RARS2's enzymatic activity. | ||||||